GCV Toxicity Curve for NIT-1 Cells




FIG. 1A




FIG. 1B

"Promoter Driven Tissue Specific Cytotoxic Agents and Methods of Use" Inventors: F. Charles Brunicardi, Ph.D. Atty.: Tamsen Valoir, Ph.D. (713) 951-3381 Atty. Docket No.: 60710-00002USC1

2/9








FIG. 2












FIG. 5C

"Promoter Driven Tissue Specific Cytotoxic Agents and Methods of Use" Inventors: F. Charles Brunicardi, Ph.D. Atty.: Tamsen Valoir, Ph.D. (713) 951-3381 Atty. Docket No.: 60710-00002USC1

6/9




FIG. 6A




FIG. 6B

Insulin Secretion SSTR-5-KO




FIG. 7

8/9






FIG. 8

"Promoter Driven Tissue Specific Cytotoxic Agents and Methods of Use" Inventors: F. Charles Brunicardi, Ph.D. Atty.: Tamsen Valoir, Ph.D. (713) 951-3381 Atty. Docket No.: 60710-00002USC1

Percent Cell Survival NIT-1





p<0.05 via student t-test, n=48 per construct

FIG. 9